Therapeutic Glycoprotein Development Services

Therapeutic glycoproteins have become the fastest growing fields in the pharmaceutical industry. With first-in-class technologies and experienced scientists, Creative Biolabs has successfully developed versatile glycoprotein production platforms. Based on these cutting-edge platforms, we can provide our worldwide clients with the largest and most diverse portfolio of standard or custom therapeutic glycoprotein services. As your best partner, Creative Biolabs is very glad to revolutionize your particular project and promote your success based on the values of quality, timing, and price.

Fig.1 Structure of glycan and glycoprotein (Lyons, 2015).

Background of Therapeutic Glycoprotein

Therapeutic glycoprotein is a type of proteins that contain oligosaccharide chains (glycans) covalently attached to amino acid side-chains. Glycoproteins are generated by glycosylation, which is a very critical modification of therapeutic proteins, known to significantly modulate yield, bioactivity, solubility, stability against proteolysis, immunogenicity, and clearance rate from circulation. It is documented that all of the key molecules involved in the immune response are glycoproteins and many therapeutic proteins like vaccines, antibodies and enzymes require glycans to have full biological activity.

Therapeutic Glycoprotein Development in Creative Biolabs

Creative Biolabs has developed versatile Glyco-engineered Systems for Therapeutic Glycoprotein Development, which are more suitable for the production of defucosylated antibodies and fully humanized glycoproteins. We provide a wide range of cells from various origins, including yeast cells, plant cells, and various mammalian cell lines. Our advanced technology overcomes shortcomings in non-mammalian expression systems. Our repertoire of mammalian cells includes a variety of cell lines such as Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, human fibrosarcoma cells, human embryonic kidney (HEK293) cells, and human HT-1080 cells, ensuring a suitable match for your specific project requirements.

In addition, we improve the cell culture media for our glycoprotein production cells. Serum is essential for cell culture in vitro, but it is expensive and exists a high risk of adventitious agents. To substitute for serum in cell cultures, some adventitious agents such as albumin, transferrin, and insulin have been used for glycosylated proteins production. Our serum-free media (SFM) with no animal-derived components has become an industry standard and is preferred for large-scale production with low cost. The proprietary cell culture media can support the growth of most industrially relevant cell lines with high cell densities (>10 million cells/mL) and specific growth rates.

Fig.2 Glycosylation pathway in a CHO cell line (Hossler, 2009).

Proprietary Cell Lines in Creative Biolabs

The specific human cell lines are generated by glycoengineering, which are more productive and cost-effective.

HighSialo-Cell line: It is used for the production of biopharmaceuticals with high sialylation and high core fucosylation.
Sialo-Cell line: It is used for the production of biopharmaceuticals with gradual adjustment of the sialylation degree.
Fuco-Cell line: It is used for the production of biopharmaceuticals with gradual adjustment of the fucosylation degree.

Advantages of our Therapeutic Glycoprotein Development Platforms

Based on our platform, we can produce a variety of glycosylated biopharmaceuticals and optimize the glycosylation to improve activity and/or other properties like bioavailability, stability, and/or immunogenicity for better clinical performance.

Consistency (minimized batch-to-batch variations)
High efficiency (homogenous, stable and fully human glycosylated biomolecules)
Low-cost with stable protein quality and high yield
Cost effective for large-scale production
Best after-sale service

Applications of Our Cutting-edge Platforms

Hormones (e.g., follicle-stimulating hormone, FSH)
Different antibodies subtypes (IgG, IgM, IgA, etc.)
Bispecific and defucosylated antibodies
Blood factors
Enzymes
Glycosylated proteins that are difficult-to-express
Fusion proteins with extended serum half-life

In addition, our advanced platform based on proprietary glycoengineered human cell lines is also beneficial for the optimization of glycosylation, which may avoid severe immunogenic reactions.

Let's Work Together to Fulfil Your Glycoprotein Project

Creative Biolabs has successfully completed a lot of therapeutic glycoprotein projects. It is exciting to offer our off-the-shelf product portfolio and services to help you get landmark development. We can customize our offering to meet your specific project needs. If you are interested, please contact us for more information.

References

Lyons, J.J.; et al. Glycans instructing immunity: the emerging role of altered glycosylation in clinical immunology. Front Pediatr. 2015, 3:54.
Hossler, P.; et al. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology. 2009, 19(9):936-49.

For Research Use Only.

Glyco-engineered Systems for Therapeutic Glycoprotein Development